The Overlooked Hormone That Could Reverse Aging

What if the key to reversing aging lay not in a fountain of youth, but in a hormone that most people overlook? Dr. Florence Comite, an endocrinologist with three decades of experience, argues that testosterone—often dismissed as a male hormone—is a critical factor in maintaining vitality for both genders. Her research, detailed in a recent guide, challenges conventional wisdom by linking low testosterone levels to a cascade of health issues, from diminished libido to increased risk of heart disease and diabetes. Could the medical community be missing a vital piece of the aging puzzle?

Testosterone's role extends far beyond sexual function. It influences muscle mass, bone density, and even cognitive performance. Yet, its impact on cardiovascular health remains under-discussed. Consider the case of Dick, a 57-year-old man who survived a heart attack only to face a bleak prognosis. His free testosterone levels—measured in picograms per millilitre (pg/ml)—were abysmal: 40 pg/ml, lower than those of a ten-year-old boy. This metric, which reflects unbound hormone available to act on tissues, is often ignored in standard blood tests. Why? Because the NHS sets a "normal" range at 190 pg/ml for men, a threshold Dr. Comite argues is far too low for optimal health.

The transformation that followed Dick's testosterone injections was nothing short of remarkable. Within weeks, his levels soared to 160 pg/ml, and he reported feeling "younger, more vibrant, and totally functional." But the real surprise came three years later: an MRI revealed his heart muscle had healed, with ejection fraction—measuring the heart's pumping ability—doubling from its post-attack state. His cardiologist, stunned by the results, called Dr. Comite to inquire about the treatment. This isn't an isolated case. Patients who received testosterone therapy after heart attacks showed similar improvements, suggesting a potential breakthrough in cardiac recovery.

Yet, the broader implications of these findings raise urgent questions. If free testosterone levels are a biomarker of systemic health, why do current guidelines fail to reflect this? How many patients are being misdiagnosed or undertreated because their hormone levels are not properly assessed? Dr. Comite's work underscores a growing disconnect between scientific evidence and clinical practice. Her research suggests that raising free testosterone to 180–250 pg/ml for men and 18–25 pg/ml for women could mitigate age-related decline, but such recommendations challenge established norms.

The public's well-being hinges on whether these insights are adopted widely. Should regulatory bodies update their standards to align with emerging evidence? Can healthcare providers be trained to prioritize free testosterone testing as a routine measure? The stakes are high: heart disease, diabetes, and osteoporosis cost lives and economies annually. If testosterone therapy offers a viable solution, why is its use still stigmatized or restricted in many regions?

For now, Dick's story stands as a testament to what's possible. At 76, he continues his treatment, proof that the body's capacity to heal may be more resilient than we assume. But his journey also highlights a paradox: modern medicine excels at treating symptoms but often ignores the root causes of aging. As Dr. Comite's work gains traction, the question becomes not whether testosterone should be embraced, but how quickly society can adapt to its potential.

Davina McCall has become a prominent figure in the conversation around hormone therapy, crediting her midlife vitality to testosterone supplementation. Her public advocacy has been linked to a tenfold rise in testosterone use among women in the UK, sparking both interest and debate in medical circles. Testosterone's role in cardiovascular health is a focal point of this discussion. Research by Dick and others has shown that testosterone enhances the heart's ability to pump blood efficiently, a critical factor in maintaining circulatory function. The heart, as a muscular organ, benefits from testosterone's dual effects on muscle strength and exercise capacity. These findings have led some physicians to argue that waiting for symptoms or life-threatening events before initiating testosterone supplementation is outdated. Instead, a proactive approach—administering testosterone to patients in their 30s or even late teens under specific medical conditions—is gaining traction.

Clinical studies underscore testosterone's broader implications for health. A 2021 study in the *Canadian Journal of Cardiology* revealed that men with the lowest testosterone levels had a 40% higher risk of dying within 20 years compared to those with higher levels. More recent research published in the *Annals of Internal Medicine* in 2024 confirmed a correlation between low testosterone and reduced lifespan in men. For women, a 2023 review in the *Journal of the Endocrine Society* highlighted that combining testosterone with estrogen therapy reduces postmenopausal women's risk of heart disease. A 2023 study in *Nature Scientific Reports* further demonstrated that testosterone levels in women aged 40 to 60 correlated with increased bone mineral density in the lumbar spine, suggesting its potential as a complementary treatment to estrogen for bone health.

Despite these benefits, some physicians remain cautious about testosterone replacement therapy (TRT). Early studies raised concerns about increased risks of heart attack and stroke, but a landmark 2023 study in the *New England Journal of Medicine* tracked over 5,200 men with low testosterone and found no such association compared to a placebo group. This has helped shift perceptions. Similarly, the long-held belief that testosterone fuels prostate cancer has been debunked. The hypothesis originated from a 1941 study of four patients, but subsequent research has shown no causal link. Prostate cancer incidence peaks in older men, while testosterone levels naturally decline with age, contradicting the idea that supplementation increases risk.

The NHS currently does not license testosterone for use in women, though specialist doctors may still prescribe it. A 2025 study in the *European Society of Medicine* found that TRT in women improved mood, energy, cognition, bone and vascular health, and sexual function. Contrary to earlier concerns, it was not linked to higher breast cancer risk. A nine-year retrospective study of 2,377 women treated with testosterone or a combination of testosterone and estrogen showed a 35.5% reduction in breast cancer incidence. These findings challenge outdated narratives and highlight the need for updated medical guidelines.

For decades, physicians like the author have prescribed testosterone to both men and women, long before it became a public topic. The growing body of evidence suggests that testosterone therapy, when guided by biomarker assessments and tailored to individual needs, can be a powerful tool in addressing age-related health declines. As research continues to evolve, the medical community faces a pivotal moment in redefining how testosterone is perceived and prescribed, balancing caution with the potential for significant health benefits.

As an internationally recognised endocrinologist who established the Women's Health Centre at Yale University, I played a pivotal role in advancing understanding of hormonal changes in both genders. In the early 1990s, I became the first physician to identify and treat the midlife hormonal declines in men, termed 'peri-andropause' and 'andropause.' These conditions mirror the well-documented 'perimenopause' and 'menopause' in women, highlighting the universality of hormonal shifts across the lifespan. Testosterone, a hormone often associated with male physiology, exerts profound effects on metabolic health, muscle function, and bone integrity. Its ability to improve blood glucose control and insulin sensitivity is particularly critical, as it enhances the body's capacity to regulate sugar levels. Insulin sensitivity refers to how effectively cells respond to insulin, the hormone that facilitates glucose uptake from the bloodstream. When this process is impaired, glucose accumulates in the blood, increasing the risk of metabolic disorders. Testosterone acts as a prime driver of muscle repair and growth, a function that becomes increasingly vital as testosterone levels decline with age.

Hormonal changes begin subtly but progressively, with testosterone levels in both men and women declining by approximately 1-3 per cent annually starting in early adulthood. This decline is often imperceptible on the surface, as visible signs of aging—such as wrinkles—typically appear later, around the age of 30. However, the internal consequences of reduced testosterone are significant. Lower testosterone levels correlate with reduced muscle mass, which has far-reaching implications for metabolic health. Muscle tissue functions as a metabolic sink, actively absorbing glucose from the bloodstream. When muscle mass diminishes, glucose remains in circulation or is stored as visceral fat around vital organs, such as the liver and heart. This fat is metabolically active, secreting inflammatory cytokines and toxins that contribute to systemic inflammation. These processes are implicated in the development of type 2 diabetes, metabolic syndrome, and neurodegenerative conditions like Alzheimer's disease. Research has established a strong association between low testosterone and these conditions, with 33.3 per cent of men over 65 in the United States exhibiting both low testosterone and diabetes. A 2023 study published in the *Journal of Endocrinology* found that testosterone replacement therapy (TRT) over two years can reduce diabetes risk by 40 per cent, surpassing the benefits achievable through lifestyle modifications alone.

The consequences of testosterone decline extend beyond metabolic health. Sarcopenia, the progressive loss of skeletal muscle mass and strength, is a direct result of declining testosterone levels. This condition compromises overall physical strength and stability, with cascading effects on energy metabolism. Muscle is a metabolically active tissue that consumes energy even at rest. Greater muscle mass enhances the body's efficiency in converting food into usable energy, a process critical for maintaining metabolic balance. For women, sarcopenia is particularly impactful due to their naturally lower peak muscle mass compared to men. Women reach their peak muscle mass in their early to mid-30s, a period coinciding with the initial decline in testosterone levels. This overlap means that women experience the negative effects of muscle loss earlier in life, often manifesting in reduced bone density and increased fracture risk. While sarcopenia is widely acknowledged, the role of testosterone in bone health is less commonly discussed but equally vital.

Testosterone exerts a direct influence on bone density by stimulating osteoblasts, the cells responsible for bone formation and turnover. As testosterone levels decline, osteoblast activity diminishes, leading to reduced bone density. This decline sets the stage for osteopenia—a precursor to osteoporosis—and eventually osteoporosis itself. Historically, osteoporosis has been perceived as a condition predominantly affecting women, but recent studies indicate that approximately 25 per cent of men also suffer from osteoporosis. The onset of bone loss in men typically occurs about a decade later than in women, largely due to men's naturally higher testosterone levels. Strong muscles and bones are essential for aging successfully, as they reduce the risk of falls—a leading cause of mortality in older adults. Testosterone supplementation can play a crucial role in mitigating muscle and bone loss, as evidenced by my personal experience and clinical observations.

Over the past three decades, I have taken testosterone supplementation due to my family history of osteoporosis. My father and aunt both suffered from severe osteoporosis, with my aunt's condition ultimately contributing to her death from lung compression caused by low oxygen levels. My mother experienced bone loss and physical shrinkage, but her condition stabilised when she began testosterone therapy. Long-term testosterone use has significantly impacted my health, as documented by DEXA scans showing preserved bone density and increased muscle mass. In contrast, my identical twin sister, who has taken testosterone for only ten years, exhibits early signs of spinal osteoporosis and osteopenia in both hips. Her body composition reflects less muscle and higher body fat compared to mine. These observations underscore the importance of testosterone in maintaining musculoskeletal health. I have prescribed testosterone to patients younger than one might expect, often prioritising bone and muscle health as a preventive measure against age-related decline.

Testosterone replacement therapy (TRT) is a medical intervention that has gained increasing attention for its potential to address hormonal imbalances in both men and women. In clinical practice, physicians often prescribe testosterone to young men in their teens and 20s whose blood tests reveal deficiencies or symptoms such as muscle loss. These cases frequently stem from disruptions during puberty, such as traumatic events like car accidents, or conditions like varicoceles—enlarged veins in the testicles that can impair hormone production. Such interventions aim to restore normal testosterone levels, which are essential for maintaining muscle mass, bone density, and overall metabolic health.

For women, TRT is sometimes initiated a decade or more before perimenopause, particularly among those who use oral contraceptives as early as age 18. The Pill, while effective for contraception, can suppress testosterone production, leading to increased body fat and reduced muscle tone. Low testosterone in women has also been associated with cognitive decline, memory issues, and mental fog. Research underscores the importance of testosterone receptors in the brain, which are critical for focus, learning, and mental clarity. Clinical observations suggest that raising testosterone levels can alleviate symptoms of "brain fog" and may even reduce the risk of Alzheimer's disease. A 2022 study published in *Reviews in Endocrine and Metabolic Disorders* highlights testosterone's neuroprotective properties, noting that low levels correlate with accelerated amyloid plaque accumulation—a hallmark of Alzheimer's.

Biological aging is a universal process, and declining testosterone levels are a natural part of this trajectory. However, TRT is not a universal solution. It should be considered only when blood tests confirm a deficiency, and it is most effective when paired with a protein-rich diet and resistance training, such as weightlifting. These lifestyle choices amplify testosterone's ability to build and maintain muscle, which is vital for longevity and vitality. Muscle mass, after all, is a cornerstone of physical resilience, and testosterone acts as one of its primary architects.

The insights presented here are adapted from *Invincible* by Florence Comite (Cornerstone, £22), to be published April 30. © Florence Comite 2026. To order a copy for £19.80 (offer valid until April 25, 2026; UK P&P free on orders over £25), visit books.mailshop.co.uk or call 020 3176 2937.